Are you Dr. Podrebarac?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
245 1st St
Ste 16
Cambridge, MA 02142Phone+1 617-301-7076Fax+1 617-301-7030
Summary
- Dr. Theresa Podrebarac, MD is a rheumatologist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Massachusetts.
Education & Training
University of Western OntarioClass of 1990
Certifications & Licensure
MA State Medical License 1996 - 2015
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis Start of enrollment: 2007 Oct 01
- A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) Start of enrollment: 2019 Jan 09
Publications & Presentations
PubMed
- 118 citationsCadherin-11 Provides Specific Cellular Adhesion between Fibroblast-like SynoviocytesXavier Valencia, Jonathan M.G. Higgins, Hans P. Kiener, David Lee, Theresa Podrebarac
The Journal of Experimental Medicine. 2004-12-20 - 397 citationsMurine CD1d-Restricted T Cell Recognition of Cellular LipidsJenny E. Gumperz, Christopher L. Roy, Anna Makowska, Deirdre Lum, Masahiko Sugita
Immunity. 2000-02-01 - 160 citationsDiverse TCRs Recognize Murine CD1Samuel M. Behar, Theresa Podrebarac, Chad J. Roy, Chyung Ru Wang, Michael B. Brenner
Journal of Immunology. 1999-01-01
Press Mentions
Horizon Therapeutics Plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus ErythematosusJanuary 4th, 2023- Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (Pegloticase Injection) plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA MonotherapyJune 1st, 2022
- First IPF Patient Enrolled in Phase 2b Trial of Oral HZN-825January 25th, 2022
- Join now to see all
Professional Memberships
- Fellow
